Fuzzyfuzzy
2021-07-23
Lol
UPDATE 1-U.S. CDC advisers back J&J COVID-19 vaccine benefits amid neurological illness reports<blockquote>更新1-美国。CDC顾问在神经系统疾病报告中支持强生COVID-19疫苗的益处</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":172735521,"tweetId":"172735521","gmtCreate":1626993626863,"gmtModify":1631887626678,"author":{"id":3576849200483737,"idStr":"3576849200483737","authorId":3576849200483737,"authorIdStr":"3576849200483737","name":"Fuzzyfuzzy","avatar":"https://static.tigerbbs.com/83fbe5cf3fa66c4ec89abe62d2856950","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Lol</p></body></html>","htmlText":"<html><head></head><body><p>Lol</p></body></html>","text":"Lol","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/172735521","repostId":2153706666,"repostType":2,"repost":{"id":"2153706666","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1626980650,"share":"https://www.laohu8.com/m/news/2153706666?lang=zh_CN&edition=full","pubTime":"2021-07-23 03:04","market":"us","language":"en","title":"UPDATE 1-U.S. CDC advisers back J&J COVID-19 vaccine benefits amid neurological illness reports<blockquote>更新1-美国。CDC顾问在神经系统疾病报告中支持强生COVID-19疫苗的益处</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2153706666","media":"Reuters","summary":"(Adds comments from meeting) July 22 (Reuters) - Despite reports of a rare neurological disorder a","content":"<p><html><body>(Adds comments from meeting)</p><p><blockquote><html><body>（添加会议中的注释）</body></html></blockquote></p><p> July 22 (Reuters) - Despite reports of a rare neurological disorder appearing in some people who have received Johnson & Johnson's COVID-19 vaccine, the benefits of its use outweigh the risks, a U.S. Centers for Disease Control and Prevention advisory panel said on Thursday.</p><p><blockquote>路透7月22日-美国疾病控制与预防中心顾问小组周四表示，尽管有报道称一些接种强生公司COVID-19疫苗的人出现了罕见的神经系统疾病，但使用该疫苗的好处大于风险。</blockquote></p><p> The U.S. Food and Drug Administration last week added a warning to its fact sheet for J&J's single-shot vaccine saying that data suggests there is an increased risk of Guillain-Barré syndrome <a href=\"https://laohu8.com/S/GBS\">$(GBS)$</a> in the six weeks after vaccination. </p><p><blockquote>美国。美国食品和药物管理局上周在强生单针疫苗的情况说明书中添加了警告，称数据表明格林-巴利综合症的风险增加<a href=\"https://laohu8.com/S/GBS\">$(GBS)$</a>接种疫苗后的六周内。</blockquote></p><p> The CDC advisory panel evaluated the J&J vaccine's risks and benefits after these preliminary reports of GBS from people who have gotten the shot. </p><p><blockquote>疾病预防控制中心顾问小组在收到接种疫苗的人关于GBS的初步报告后，评估了强生疫苗的风险和益处。</blockquote></p><p> Given the possible association between GBS and the vaccine, CDC will update its considerations for the use of J&J's vaccine to say that patients with a history of GBS should first look at the availability of two-shot mRNA-based vaccines from Pfizer Inc</p><p><blockquote>鉴于GBS与疫苗之间可能存在关联，CDC将更新其使用强生疫苗的考虑因素，表示有GBS病史的患者应首先查看辉瑞公司基于mRNA的两针疫苗的可用性</blockquote></p><p> /<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> and Moderna , an agency official said. </p><p><blockquote>/<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>和Moderna，一位机构官员说。</blockquote></p><p> The FDA cited 100 preliminary reports of GBS in J&J vaccine recipients including 95 serious cases that required hospitalization and <a href=\"https://laohu8.com/S/AONE.U\">one</a> reported death.</p><p><blockquote>FDA引用了100份强生疫苗接种者GBS的初步报告，其中包括95份需要住院治疗的严重病例<a href=\"https://laohu8.com/S/AONE.U\">一</a>报告死亡。</blockquote></p><p> J&J on Thursday said the known benefits on its vaccine outweigh known potential risks. </p><p><blockquote>强生周四表示，其疫苗的已知益处超过了已知的潜在风险。</blockquote></p><p> Members of a work group of the CDC Advisory Committee on Immunization Practices (ACIP) expressed \"strong support\" for continued use of J&J vaccine, the CDC's Sarah Mbaeyi said during the panel meeting. </p><p><blockquote>CDC免疫实践咨询委员会（ACIP）工作组成员对继续使用J&J疫苗表示“强烈支持”，CDC的Sarah Mbaeyi在小组会议上说。</blockquote></p><p> The CDC will also update some of its communication materials on the vaccine, including information for medical providers on talking to patients about vaccine safety and frequently asked questions, Mbaeyi added.</p><p><blockquote>Mbaeyi补充说，疾病预防控制中心还将更新一些关于疫苗的交流材料，包括医疗提供者与患者谈论疫苗安全性和常见问题的信息。</blockquote></p><p> (Reporting by Manojna Maddipatla in Bengaluru; Editing by Will Dunham)</p><p><blockquote>（Manojna Maddipatla班加罗尔报道；Will Dunham编辑）</blockquote></p><p>((manojna.kalyani@thomsonreuters.com; +91 8061822700;))</p><p><blockquote>（（manojna.kalyani@thomsonreuters.com；+91 806 182 270 00；））</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UPDATE 1-U.S. CDC advisers back J&J COVID-19 vaccine benefits amid neurological illness reports<blockquote>更新1-美国。CDC顾问在神经系统疾病报告中支持强生COVID-19疫苗的益处</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUPDATE 1-U.S. CDC advisers back J&J COVID-19 vaccine benefits amid neurological illness reports<blockquote>更新1-美国。CDC顾问在神经系统疾病报告中支持强生COVID-19疫苗的益处</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2021-07-23 03:04</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><body>(Adds comments from meeting)</p><p><blockquote><html><body>（添加会议中的注释）</body></html></blockquote></p><p> July 22 (Reuters) - Despite reports of a rare neurological disorder appearing in some people who have received Johnson & Johnson's COVID-19 vaccine, the benefits of its use outweigh the risks, a U.S. Centers for Disease Control and Prevention advisory panel said on Thursday.</p><p><blockquote>路透7月22日-美国疾病控制与预防中心顾问小组周四表示，尽管有报道称一些接种强生公司COVID-19疫苗的人出现了罕见的神经系统疾病，但使用该疫苗的好处大于风险。</blockquote></p><p> The U.S. Food and Drug Administration last week added a warning to its fact sheet for J&J's single-shot vaccine saying that data suggests there is an increased risk of Guillain-Barré syndrome <a href=\"https://laohu8.com/S/GBS\">$(GBS)$</a> in the six weeks after vaccination. </p><p><blockquote>美国。美国食品和药物管理局上周在强生单针疫苗的情况说明书中添加了警告，称数据表明格林-巴利综合症的风险增加<a href=\"https://laohu8.com/S/GBS\">$(GBS)$</a>接种疫苗后的六周内。</blockquote></p><p> The CDC advisory panel evaluated the J&J vaccine's risks and benefits after these preliminary reports of GBS from people who have gotten the shot. </p><p><blockquote>疾病预防控制中心顾问小组在收到接种疫苗的人关于GBS的初步报告后，评估了强生疫苗的风险和益处。</blockquote></p><p> Given the possible association between GBS and the vaccine, CDC will update its considerations for the use of J&J's vaccine to say that patients with a history of GBS should first look at the availability of two-shot mRNA-based vaccines from Pfizer Inc</p><p><blockquote>鉴于GBS与疫苗之间可能存在关联，CDC将更新其使用强生疫苗的考虑因素，表示有GBS病史的患者应首先查看辉瑞公司基于mRNA的两针疫苗的可用性</blockquote></p><p> /<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> and Moderna , an agency official said. </p><p><blockquote>/<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>和Moderna，一位机构官员说。</blockquote></p><p> The FDA cited 100 preliminary reports of GBS in J&J vaccine recipients including 95 serious cases that required hospitalization and <a href=\"https://laohu8.com/S/AONE.U\">one</a> reported death.</p><p><blockquote>FDA引用了100份强生疫苗接种者GBS的初步报告，其中包括95份需要住院治疗的严重病例<a href=\"https://laohu8.com/S/AONE.U\">一</a>报告死亡。</blockquote></p><p> J&J on Thursday said the known benefits on its vaccine outweigh known potential risks. </p><p><blockquote>强生周四表示，其疫苗的已知益处超过了已知的潜在风险。</blockquote></p><p> Members of a work group of the CDC Advisory Committee on Immunization Practices (ACIP) expressed \"strong support\" for continued use of J&J vaccine, the CDC's Sarah Mbaeyi said during the panel meeting. </p><p><blockquote>CDC免疫实践咨询委员会（ACIP）工作组成员对继续使用J&J疫苗表示“强烈支持”，CDC的Sarah Mbaeyi在小组会议上说。</blockquote></p><p> The CDC will also update some of its communication materials on the vaccine, including information for medical providers on talking to patients about vaccine safety and frequently asked questions, Mbaeyi added.</p><p><blockquote>Mbaeyi补充说，疾病预防控制中心还将更新一些关于疫苗的交流材料，包括医疗提供者与患者谈论疫苗安全性和常见问题的信息。</blockquote></p><p> (Reporting by Manojna Maddipatla in Bengaluru; Editing by Will Dunham)</p><p><blockquote>（Manojna Maddipatla班加罗尔报道；Will Dunham编辑）</blockquote></p><p>((manojna.kalyani@thomsonreuters.com; +91 8061822700;))</p><p><blockquote>（（manojna.kalyani@thomsonreuters.com；+91 806 182 270 00；））</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153706666","content_text":"(Adds comments from meeting) July 22 (Reuters) - Despite reports of a rare neurological disorder appearing in some people who have received Johnson & Johnson's COVID-19 vaccine, the benefits of its use outweigh the risks, a U.S. Centers for Disease Control and Prevention advisory panel said on Thursday. The U.S. Food and Drug Administration last week added a warning to its fact sheet for J&J's single-shot vaccine saying that data suggests there is an increased risk of Guillain-Barré syndrome $(GBS)$ in the six weeks after vaccination. The CDC advisory panel evaluated the J&J vaccine's risks and benefits after these preliminary reports of GBS from people who have gotten the shot. Given the possible association between GBS and the vaccine, CDC will update its considerations for the use of J&J's vaccine to say that patients with a history of GBS should first look at the availability of two-shot mRNA-based vaccines from Pfizer Inc /BioNTech SE and Moderna , an agency official said. The FDA cited 100 preliminary reports of GBS in J&J vaccine recipients including 95 serious cases that required hospitalization and one reported death. J&J on Thursday said the known benefits on its vaccine outweigh known potential risks. Members of a work group of the CDC Advisory Committee on Immunization Practices (ACIP) expressed \"strong support\" for continued use of J&J vaccine, the CDC's Sarah Mbaeyi said during the panel meeting. The CDC will also update some of its communication materials on the vaccine, including information for medical providers on talking to patients about vaccine safety and frequently asked questions, Mbaeyi added. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Will Dunham)((manojna.kalyani@thomsonreuters.com; +91 8061822700;))","news_type":1,"symbols_score_info":{"JNJ":0.9}},"isVote":1,"tweetType":1,"viewCount":332,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/172735521"}
精彩评论